In Situ Immune Parameters and Their Prognostic Role on the Survival of Patients With Glioblastoma

Primary objective :

The primary objective is to determine for each of the 3 molecular subtypes of glioblastoma the predictive performance on 1-year overall survival of in situ immune parameters

Secondary objectives :

To identify the best combination of in vivo immune parameters that is predictive of 1-year overall survival To determine the impact of immune parameters on overall survival Create a collection of biological samples

Inclusion criteria

• Patients with newly diagnosed, brain tumor
• Gross or near total resection of the contrast-enhancing tumor mass decides by the neurosurgeron.
• Subjects ≥18 and ≤75 years of age at surgery
• Patients must be able to understand and sign the informed consent documents indicating that they are aware of the investigational nature of this study.
• Confirmation of the diagnosis of grade IV GBM by the local pathologist with an independent neuropathologist who will review this diagnosis
• Primary therapy must consist of surgical resection with the intent for a gross or near total resection of the contrast-enhancing tumor mass, followed by conventional external beam radiation therapy and concurrent temozolomide chemotherapy.
• Tumor biopsy for biological analysis has to be performed before using ultrasonic surgery

Exclusion criteria

• Patient with other type of primary brain tumor or metastases
• Patients with only biopsy performed for the diagnosis
• Subjects under guardianship, curatorship or judicial protection
• Female subjects who are pregnant or breast-feeding